Zevra Therapeutics, Inc. (ZVRA) Tops Q2 EPS by 3c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q2 EPS of $0.14, $0.03 better than the analyst estimate of $0.11. Revenue for the quarter came in at $39.7 million versus the consensus estimate of $34.17 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs sees bond markets as speed limiter for stocks
• Apple (AAPL) call put ratio 1.1 calls 1 put into hosting a special event